Residual anatomical disease in diffuse large B-cell lymphoma patients with FDG-PET-based complete response after first-line R-CHOP therapy: Does it have any prognostic value?

Hugo J A Adams; John M H De Klerk; Rob Fijnheer; Ben G F Heggelman; Stefan V. Dubois; Rutger A J Nievelstein; Thomas C. Kwee

doi:10.1097/RCT.0000000000000270

Residual anatomical disease in diffuse large B-cell lymphoma patients with FDG-PET-based complete response after first-line R-CHOP therapy: Does it have any prognostic value?

Hugo J A Adams^*, John M H De Klerk, Rob Fijnheer, Ben G F Heggelman, Stefan V. Dubois, Rutger A J Nievelstein, Thomas C. Kwee

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Objective: This study aimed to determine the prognostic value of residual anatomical disease, including its size and reduction relative to baseline, in diffuse large B-cell lymphoma patients who have 18F-fluoro-2-deoxy-D-glucose positron emission tomography-based complete response after first-line R-CHOP therapy. Methods: This retrospective study included 47 patients. In patients with computed tomography (CT)-based residual disease, the size of the largest residual lesion (Res<inf>max</inf>) and the sum of the sizes of all residual lesions (Res<inf>total</inf>) were measured, and their reductions relative to baseline (ΔRes<inf>max</inf> and ΔRes<inf>total</inf>) were calculated. Results: Patients with high-risk National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) scores had significantly lower progression-free survival (PFS) and overall survival (OS) than patients with low-risk NCCN-IPI scores (P = 0.032 and P = 0.022). In contrast, patients with residual lesions at CT had no significantly lower PFS and OS than those without (P = 0.531 and P = 0.801). In the subpopulation with CT-based residual disease, patients with high Res<inf>max</inf>, high Res<inf>total</inf>, low ΔRes<inf>max</inf>, and low ΔRes<inf>total</inf> had no significantly different PFS and OS than those with low Res<inf>max</inf>, low Res<inf>total</inf>, high ΔRes<inf>max</inf>, and high ΔRes<inf>total</inf> (P = 0.980 and P = 0.790, P = 0.423 and P = 0.229, P = 0.923 and P = 0.893, and P = 0.923 and P = 0.893, respectively). Conclusions: The NCCN-IPI retains its prognostic value in diffuse large B-cell lymphoma patients with <sup>18</sup>F-fluoro-2-deoxy-D-glucose positron emission tomography-based complete response after first-line R-CHOP therapy. However, the presence of residual anatomical disease, including its size and reduction relative to baseline, has no prognostic value in these patients.

Original language	English
Pages (from-to)	810-815
Number of pages	6
Journal	Journal of Computer Assisted Tomography
Volume	39
Issue number	5
DOIs	https://doi.org/10.1097/RCT.0000000000000270
Publication status	Published - 1 Sept 2015

Keywords

Diffuse large B-cell lymphoma
FDG-PET/CT
Posttreatment
Prognosis
Residual disease

Access to Document

10.1097/RCT.0000000000000270

Cite this

Adams, H. J. A., De Klerk, J. M. H., Fijnheer, R., Heggelman, B. G. F., Dubois, S. V., Nievelstein, R. A. J., & Kwee, T. C. (2015). Residual anatomical disease in diffuse large B-cell lymphoma patients with FDG-PET-based complete response after first-line R-CHOP therapy: Does it have any prognostic value? Journal of Computer Assisted Tomography, 39(5), 810-815. https://doi.org/10.1097/RCT.0000000000000270

@article{33ad208ae1544818a7713ca521d12e60,

title = "Residual anatomical disease in diffuse large B-cell lymphoma patients with FDG-PET-based complete response after first-line R-CHOP therapy: Does it have any prognostic value?",

abstract = "Objective: This study aimed to determine the prognostic value of residual anatomical disease, including its size and reduction relative to baseline, in diffuse large B-cell lymphoma patients who have 18F-fluoro-2-deoxy-D-glucose positron emission tomography-based complete response after first-line R-CHOP therapy. Methods: This retrospective study included 47 patients. In patients with computed tomography (CT)-based residual disease, the size of the largest residual lesion (Resmax) and the sum of the sizes of all residual lesions (Restotal) were measured, and their reductions relative to baseline (ΔResmax and ΔRestotal) were calculated. Results: Patients with high-risk National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) scores had significantly lower progression-free survival (PFS) and overall survival (OS) than patients with low-risk NCCN-IPI scores (P = 0.032 and P = 0.022). In contrast, patients with residual lesions at CT had no significantly lower PFS and OS than those without (P = 0.531 and P = 0.801). In the subpopulation with CT-based residual disease, patients with high Resmax, high Restotal, low ΔResmax, and low ΔRestotal had no significantly different PFS and OS than those with low Resmax, low Restotal, high ΔResmax, and high ΔRestotal (P = 0.980 and P = 0.790, P = 0.423 and P = 0.229, P = 0.923 and P = 0.893, and P = 0.923 and P = 0.893, respectively). Conclusions: The NCCN-IPI retains its prognostic value in diffuse large B-cell lymphoma patients with 18F-fluoro-2-deoxy-D-glucose positron emission tomography-based complete response after first-line R-CHOP therapy. However, the presence of residual anatomical disease, including its size and reduction relative to baseline, has no prognostic value in these patients.",

keywords = "Diffuse large B-cell lymphoma, FDG-PET/CT, Posttreatment, Prognosis, Residual disease",

author = "Adams, {Hugo J A} and {De Klerk}, {John M H} and Rob Fijnheer and Heggelman, {Ben G F} and Dubois, {Stefan V.} and Nievelstein, {Rutger A J} and Kwee, {Thomas C.}",

year = "2015",

month = sep,

day = "1",

doi = "10.1097/RCT.0000000000000270",

language = "English",

volume = "39",

pages = "810--815",

journal = "Journal of Computer Assisted Tomography",

issn = "0363-8715",

publisher = "Lippincott Williams & Wilkins",

number = "5",

}

Adams, HJA, De Klerk, JMH, Fijnheer, R, Heggelman, BGF, Dubois, SV, Nievelstein, RAJ & Kwee, TC 2015, 'Residual anatomical disease in diffuse large B-cell lymphoma patients with FDG-PET-based complete response after first-line R-CHOP therapy: Does it have any prognostic value?', Journal of Computer Assisted Tomography, vol. 39, no. 5, pp. 810-815. https://doi.org/10.1097/RCT.0000000000000270

Residual anatomical disease in diffuse large B-cell lymphoma patients with FDG-PET-based complete response after first-line R-CHOP therapy: Does it have any prognostic value? / Adams, Hugo J A; De Klerk, John M H; Fijnheer, Rob et al.
In: Journal of Computer Assisted Tomography, Vol. 39, No. 5, 01.09.2015, p. 810-815.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Residual anatomical disease in diffuse large B-cell lymphoma patients with FDG-PET-based complete response after first-line R-CHOP therapy

T2 - Does it have any prognostic value?

AU - Adams, Hugo J A

AU - De Klerk, John M H

AU - Fijnheer, Rob

AU - Heggelman, Ben G F

AU - Dubois, Stefan V.

AU - Nievelstein, Rutger A J

AU - Kwee, Thomas C.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Objective: This study aimed to determine the prognostic value of residual anatomical disease, including its size and reduction relative to baseline, in diffuse large B-cell lymphoma patients who have 18F-fluoro-2-deoxy-D-glucose positron emission tomography-based complete response after first-line R-CHOP therapy. Methods: This retrospective study included 47 patients. In patients with computed tomography (CT)-based residual disease, the size of the largest residual lesion (Resmax) and the sum of the sizes of all residual lesions (Restotal) were measured, and their reductions relative to baseline (ΔResmax and ΔRestotal) were calculated. Results: Patients with high-risk National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) scores had significantly lower progression-free survival (PFS) and overall survival (OS) than patients with low-risk NCCN-IPI scores (P = 0.032 and P = 0.022). In contrast, patients with residual lesions at CT had no significantly lower PFS and OS than those without (P = 0.531 and P = 0.801). In the subpopulation with CT-based residual disease, patients with high Resmax, high Restotal, low ΔResmax, and low ΔRestotal had no significantly different PFS and OS than those with low Resmax, low Restotal, high ΔResmax, and high ΔRestotal (P = 0.980 and P = 0.790, P = 0.423 and P = 0.229, P = 0.923 and P = 0.893, and P = 0.923 and P = 0.893, respectively). Conclusions: The NCCN-IPI retains its prognostic value in diffuse large B-cell lymphoma patients with 18F-fluoro-2-deoxy-D-glucose positron emission tomography-based complete response after first-line R-CHOP therapy. However, the presence of residual anatomical disease, including its size and reduction relative to baseline, has no prognostic value in these patients.

AB - Objective: This study aimed to determine the prognostic value of residual anatomical disease, including its size and reduction relative to baseline, in diffuse large B-cell lymphoma patients who have 18F-fluoro-2-deoxy-D-glucose positron emission tomography-based complete response after first-line R-CHOP therapy. Methods: This retrospective study included 47 patients. In patients with computed tomography (CT)-based residual disease, the size of the largest residual lesion (Resmax) and the sum of the sizes of all residual lesions (Restotal) were measured, and their reductions relative to baseline (ΔResmax and ΔRestotal) were calculated. Results: Patients with high-risk National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) scores had significantly lower progression-free survival (PFS) and overall survival (OS) than patients with low-risk NCCN-IPI scores (P = 0.032 and P = 0.022). In contrast, patients with residual lesions at CT had no significantly lower PFS and OS than those without (P = 0.531 and P = 0.801). In the subpopulation with CT-based residual disease, patients with high Resmax, high Restotal, low ΔResmax, and low ΔRestotal had no significantly different PFS and OS than those with low Resmax, low Restotal, high ΔResmax, and high ΔRestotal (P = 0.980 and P = 0.790, P = 0.423 and P = 0.229, P = 0.923 and P = 0.893, and P = 0.923 and P = 0.893, respectively). Conclusions: The NCCN-IPI retains its prognostic value in diffuse large B-cell lymphoma patients with 18F-fluoro-2-deoxy-D-glucose positron emission tomography-based complete response after first-line R-CHOP therapy. However, the presence of residual anatomical disease, including its size and reduction relative to baseline, has no prognostic value in these patients.

KW - Diffuse large B-cell lymphoma

KW - FDG-PET/CT

KW - Posttreatment

KW - Prognosis

KW - Residual disease

UR - http://www.scopus.com/inward/record.url?scp=84941889896&partnerID=8YFLogxK

U2 - 10.1097/RCT.0000000000000270

DO - 10.1097/RCT.0000000000000270

M3 - Article

C2 - 26035406

AN - SCOPUS:84941889896

SN - 0363-8715

VL - 39

SP - 810

EP - 815

JO - Journal of Computer Assisted Tomography

JF - Journal of Computer Assisted Tomography

IS - 5

ER -

Residual anatomical disease in diffuse large B-cell lymphoma patients with FDG-PET-based complete response after first-line R-CHOP therapy: Does it have any prognostic value?

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this